What we will review this lecture: Receptor Tyrosine Kinase signalling: PI3K Pathway – AKT, PDK1, PTEN RTK Signalling in Cancer Historical description of.

Slides:

Advertisements

Similar presentations

Imatinib Resistance Geoffrey L. Uy, M.D. Associate Professor of Medicine Division of Oncology.

Advertisements

UNITID INTRODUCES THE SCREENING OF MYELOGENOUS LEUKAEMIA BY USE OF XPERT BCR –ABL MONITOR UNITID recently started screening for the Philadelphia chromosome.

Armaan Khalid. What is Leukaemia?  Cancer of the blood or bone marrow  Can be classified: Acute/chronic Myeloid/lymphoid.

LEUKEMIA—HEMATOLOGY {S1}

Cancer therapy IJsbrand Kramer

Leukemia is characterized by hyperproliferation of immature white blood cells white blood cell Leukemic patientnormal person red blood cells hyperproliferation.

PDGF β Receptor. Protein 1106 amino acid protein Weinberg Fig 5.10.

Molecular Medicine. Focus on Cancer Most chemotherapies were developed before the human genome was sequenced Many are alkylating agents that attach methyl.

Oncogenes and Chromosomal Aberrations The Story of Abl and the Philadelphia Chromosome.

This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.

Anticancer Therapy: Kinase Inhibitors Charles Harrell.

Rakesh Biswas MD Professor, Medicine, People's College of Medical Sciences, Bhopal, India Lecture first conceived and delivered to medicine undergrads.

Chronic leukemias. Chronic myelogenous (granulocytic) leukemia Is characterized by an unregulated proliferation of myeloid elements in the bone marrow,

Chronic myeloid leukaemia. THE STORY OF CHRONIC MYELOID LEUKAEMIA ‘It is moreover, the same conclusion which Bennett came to in the much-discussed matter.

Marty O’Neill II Carmen Banea

Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.

Fusion Genes in Cancer Wednesday, June 27th. Outline: Transcription Fusion genes Examples of fusion genes in cancer Summary and conclusions.

Products of haematopoiesis. Leukaemia, the current hypothesis Defect in maturation of white blood cells-may involve a block in differentiation and/or.

Hormonal Agents Estrogen & Androgen Inhibitors Gonadotropin-Releasing Hormone Agonists Aromatase Inhibitors Tamoxifen Leuprolide Aminogluthethimide.

Molecular Medicine Dr Catherine Flynn Consultant Haematologist St James’s Hospital October 22 nd 2009.

Leukemia is characterized by hyperproliferation of immature white blood cells white blood cell Leukemic patientnormal person red blood cells hyperproliferation.

Normal haemopoiesis. ABNORMALITIES IN THE HEMOPOIETIC SYSTEM CAN LEAD TO HEMOGLOBINOPATHIES HEMOPHILIA DEFECTS IN HEMOSTASIS/THROMBOSIS HEMATOLOGICAL.

Genetic Mutations that Lead to Chronic Myelogenous Leukemia: Causes and Treatments Marty O’Neill II & Carmen Banea

Here are some CML slides that may be helpful for your presentation.

Which has the Human Genome Project most improved in the field of medicine? A. the ability to generate vaccines B. the diagnosis and treatment of disease.

BIOL 445 – CANCER BIOLOGY PRESENTATION

Finding Cancer Genes.

Interesting Developments. Historic trends in biotech fields.

Chronic Myelogenous Leukemia By: Bobby Orr Danielle Heinbaugh Adam Edwards.

Case Study MICR Hematology Spring, 2011 Case # 5 Hee Jin Kim, Hooman Nikizad and Arthur Omuro.

hyperproliferation of white blood cells

Chronic myeloid leukaemia Cancer of granulocyte production Too many (non functioning) granulocytes are produced Bone marrow is overcrowded with ineffective.

Dr Nauman Butt – Royal Liverpool University Hospital CML Patient Seminar - 14 th November 2015 What is CML? How do we treat it? Get up to speed…

Molecular Monitoring in CML the process and questions we can answer Letizia Foroni.

Molecular Modeling 1. Introduction to Computational Molecular Physics 2. Molecular Mechanics 3. Conformation Searching 4. Molecular Orbital Methods 5.

Chronic myelogenous leukemia Uncommon disease Highly lethal when ineffectively Rxd Most pts are in their 50s+60s The molecular understanding of this disease.

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis.

MaGic Bullets A Case on Enzyme inhibition

Heterogeneous group of hematopoietic neoplasms Uncontrolled proliferation and decreased apoptotic activity with variable degrees of differentiation Composed.

What we will review this lecture:

Myeloproliferative disorder Clonal evolution Clonal evolution & stepwise progression to fibrosis, marrow failure or acute blast phase.

ONCOGENE AND ITS ROLE IN THE DEVELOPMENT OF LEUKAEMIA Nouf khaled al-Hajjar SUPERVISOR Dr.SAMINA HAQ.

Biology of Cancer Weeks 1 Introduction and 2 RTKs Dr. Michael Chorney Susquehanna Medicine and Health Science Magnet February 17 th -28 th, 2014.

Chronic Myeloid Leukemia

Nada Mohamed Ahmed, MD, MT (ASCP)i. Objectives chronic myeloid leukaemia (CML) Haematopoietic malignancies Polycythemia vera (PV) Idiopathic myelofibrosis.

Chronic Myelocytic Leukemia Mark D. Browning, M.D. Oncology/Hematology Associates February 26, 2016.

CLINICAL PROGRESSION INTRODUCTION METHOD CONCLUSION REFERENCES

Myeloproliferative disorder Clonal evolution Clonal evolution & stepwise progression to fibrosis, marrow failure or acute blast phase.

Chronic myelogenous leukemia (CML)

Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms

11 th lecture Chronic myeloid leukaemia By DR Fatehia Awny Faculty of Health Science Beirut Arab University

Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms

CHRONIC MYELOID LEUKEMIA (CML)

Assistant Prof. Dr. Nibras Saleam Al-Ammar PhD in Clinical Immunology

Chronic Leukemia Kristine Krafts, M.D..

LEUKEMIA By: J.U..

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Chapter 17: Regulation of cell number

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Extracellular Regulation of Apoptosis

The Akt-mTOR tango and its relevance to cancer

A presentation By Abedelaziz Taha Hammash supervisor \ Mr

Nat. Rev. Nephrol. doi: /nrneph

Chronic Leukemia Dr. Noha Noufal.

CHRONIC LEUKEMIA BY: DR. FATMA AL-QAHTANI CONSULTANT HAEMATOLOGIST

The Pathway to Progress Against Chronic Myelogenous Leukemia.

Simplified BRAF signaling network.

Macropinocytosis in PTEN-deficient prostate cancer cells drives the uptake of necrotic cell debris to support tumor cell fitness. Macropinocytosis in PTEN-deficient.

Presentation transcript:

What we will review this lecture: Receptor Tyrosine Kinase signalling: PI3K Pathway – AKT, PDK1, PTEN RTK Signalling in Cancer Historical description of BCR-ABL

Friedrich Grimminger, Ralph T. Schermuly & Hossein A. Ghofrani. Nature Reviews Drug Discovery 9,

CML: Chronic Myelogenous Leukemia – Asymptomatic at time of diagnosis Abnormal white blood cell count Stable for 3 – 5 years followed by “Blast Crisis” Fatal within 3 – 6 months of Blast crisis 20% of all leukemia's 5000 cases per year in US (compare with 180,000 lung cancer cases)

CML: Chronic Myelogenous Leukemia – All CML cells harbor Philadelphia chromosome 1960: Peter Nowell David Hungerford Nowell P, Hungerford D. "A minute chromosome in chronic granulocytic leukemia." Science 1960;132:1497.

1973: Janet D. Rowley Discovered t(9;22) Rowley JD. "A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]". Nature 1973;243:290–3.

c-Abl Kinase Domain Structure

STI-571